Biomarker development in the precision medicine era: lung cancer as a case study

Nature Reviews Cancer 16, 525 (2016). doi:10.1038/nrc.2016.56 Authors: Ashley J. Vargas & Curtis C. Harris Precision medicine relies on validated biomarkers with which to better classify patients by their probable disease risk, prognosis and/or response to treatment. Although affordable 'omics'-based technology has enabled faster identification of putative biomarkers, the validation of biomarkers is still stymied by low statistical power and
Source: Nature Reviews Cancer - Category: Cancer & Oncology Authors: Tags: Review Source Type: research